Voyager Therapeutics (VYGR) reported positive results Monday from the single ascending dose trial of its investigational antibody VY7523, developed to selectively inhibit the spread of pathological tau in Alzheimer's disease.
Data from the trial demonstrated the safety, tolerability, and dose-proportional pharmacokinetics of single intravenous doses in 48 healthy volunteers, the company said.
The drug was well tolerated across all six ascending dose cohorts, meeting the primary objective of the trial, with no serious adverse events, severe adverse events, or infusion reactions reported.
Voyager said it has initiated a multiple ascending dose trial of the drug in patients with early Alzheimer's disease, which is expected to generate initial tau positron emission tomography (PET) imaging data in H2 2026.
Voyager shares were down nearly 3% in recent trading.
Price: 3.97, Change: -0.11, Percent Change: -2.70
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。